Bioequivalence of Oral Products and the Biopharmaceutics Classification System: Science, Regulation, and Public Policy

被引：36

作者：

Amidon, K. S. ^{[2
]}

Langguth, P. ^{[3
]}

Lennernas, H. ^{[4
]}

Yu, L. ^{[5
]}

Amidon, G. L. ^{[1
]}

机构：

[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA

[2] Iowa State Univ, Dept World Languages & Cultures, Ames, IA USA

[3] Johannes Gutenberg Univ Mainz, Dept Biopharm & Pharmaceut Technol, Mainz, Germany

[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden

[5] US FDA, Off Gener Drugs, Rockville, MD 20857 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 90卷 / 03期

关键词：

INTESTINAL PERMEABILITY; UNITED-STATES; DRUG; CACO-2; BCS; FDA;

D O I：

10.1038/clpt.2011.109

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The demonstration of bioequivalence (BE) is an essential requirement for ensuring that patients receive a product that performs as indicated by the label. The BE standard for a particular product is set by its innovator, and this standard must subsequently be matched by generic drug products. The Biopharmaceutics Classification System (BCS) sets a scientific basis for an improved BE standard for immediate-release solid oral dosage forms. In this paper, we discuss BE and the BCS, as well as the issues that are currently relevant to BE as a pharmaceutical product standard.

引用

页码：467 / 470

页数：4

共 25 条

[1] A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].

AMIDON, GL ;

LENNERNAS, H ;

SHAH, VP ;

CRISON, JR .

PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420

[2]

[Anonymous], 2010, GUID INV BIOEQ

[3] The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted [J].

Benet, L. Z. ;

Larregieu, C. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (03) :405-407

[4]

Carpenter D, 2010, PRINC STUD AM POLIT, P1

[5] WHITE PAPER ON THERAPEUTIC EQUIVALENCE OF CHEMICALLY EQUIVALENT DRUGS [J].

CASTLE, WB ;

ASTWOOD, EB ;

FINLAND, M ;

KEEFER, CS .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (07) :1171-&

[6] The Use of Drug Metabolism for Prediction of Intestinal Permeability [J].

Chen, Mei-Ling ;

Yu, Lawrence .

MOLECULAR PHARMACEUTICS, 2009, 6 (01) :74-81

[7] Bioavailability and bioequivalence: An FDA regulatory overview [J].

Chen, ML ;

Shah, V ;

Patnaik, R ;

Adams, W ;

Hussain, A ;

Conner, D ;

Mehta, M ;

Malinowski, H ;

Lazor, J ;

Huang, SM ;

Hare, D ;

Lesko, L ;

Sporn, D ;

Williams, R .

PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1645-1650

[8]

DAHAN A, 2010, MOL PHARM

[9]

*DRUG BIOEQ STUD P, 1974, J PHARMACOKINET BIOP, V2, P433

[10]

FDA Guidance for Industry, 2003, BIOAV BIOEQ STUD OR

← 1 2 3 →